03486nam a22004575i 4500001001800000003000900018005001700027007001500044008004100059020001800100024003500118050001600153072001600169072002300185072001500208245021500223250001800438264006900456300006400525336002600589337002600615338003600641347002400677505066200701520094401363650001602307650002902323650001602352650003402368700008002402700008402482700008202566700008002648700008602728710003402814773002602848776003602874776003602910776003602946856004602982978-3-031-53659-5DE-He21320251030112000.0cr nn 008mamaa240418s2024    sz |    s    |||| 0|eng d  a97830315365957 a10.1007/978-3-031-53659-52doi 4aRC666-701.2 7aMJD2bicssc 7aMED0100002bisacsh 7aMJD2thema10aCardiovascular Considerations in Hematopoietic Stem Cell Transplantationh[electronic resource] /cedited by Azin Alizadehasl, Ardeshir Ghavamzadeh, Amir Hossein Emami, Ghasem Janbabaei, Davood Khoda-Amorzideh.  a1st ed. 2024. 1aCham :bSpringer Nature Switzerland :bImprint: Springer,c2024.  aVI, 291 p. 37 illus., 34 illus. in color.bonline resource.  atextbtxt2rdacontent  acomputerbc2rdamedia  aonline resourcebcr2rdacarrier  atext filebPDF2rda0 aHSCT at a glance -- Burden of cardiovascular disease in HSCT -- Risk factors and Mechanisms of Cardiotoxicity in HSCT -- Cardiotoxicity of commonly used drugs in HSCT -- Pre-HSCT cardiovascular evaluation -- HSCT in low EF patients -- Arrhythmias and conduction disorders in HSCT -- Coronary and peripheral arterial disease in HSCT -- Thrombotic disease in HSCT -- Pulmonary hypertension in HSCT -- Pericardial disease in HSCT -- Metabolic syndrome in HSCT -- HSCT in patients with cardiac amyloidosis -- HSCT in patients with autoimmune conditions, sickle cell anaemia and thalassemia -- Cardiotoxicity surveillance and cardioprotective strategies in HSCT.  aThis book discusses the epidemiology and the known cardiotoxic effects of chemoradiation agents in addition to newer therapies in hematopoietic stem cell transplantation (HSCT). Recent expert consensus statements from cardiology and hematology/oncology societies are reviewed in regard to risk stratification of the patient based on the type of treatments they are undergoing. Finally, gaps in knowledge are identified with proposed avenues of research that allow for more accurate risk assessment, prediction and potential treatment of the HSCT patient in attenuating the risk of developing cardiovascular comorbidities. Cardiovascular Considerations in Hematopoietic Stem Cell Transplantation reveals a picture of effective management of these patients in order to optimize both short- and long-term outcomes of HSCT. It is of considerable interest to all involved or training within this rapidly growing area of cardiology and oncology. 0aCardiology. 0aCancerxGenetic aspects.14aCardiology.24aCancer Genetics and Genomics.1 aAlizadehasl, Azin.eeditor.4edt4http://id.loc.gov/vocabulary/relators/edt1 aGhavamzadeh, Ardeshir.eeditor.4edt4http://id.loc.gov/vocabulary/relators/edt1 aEmami, Amir Hossein.eeditor.4edt4http://id.loc.gov/vocabulary/relators/edt1 aJanbabaei, Ghasem.eeditor.4edt4http://id.loc.gov/vocabulary/relators/edt1 aKhoda-Amorzideh, Davood.eeditor.4edt4http://id.loc.gov/vocabulary/relators/edt2 aSpringerLink (Online service)0 tSpringer Nature eBook08iPrinted edition:z978303153658808iPrinted edition:z978303153660108iPrinted edition:z978303153661840uhttps://doi.org/10.1007/978-3-031-53659-5